Royalty Pharma delivered robust 2025 results, with Q4 receipts up 17% to $856 million and full-year portfolio receipts at $3.25 billion. The company deployed $2.6 billion into 9 new royalties and ...
Gold royalty stocks regain focus as oil-driven cost pressure weighs on miners while Franco-Nevada, Wheaton and Royal Gold stand apart.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results